How does aspartame pricing compare to bulk APIs in China's generics market?

How does aspartame pricing compare to bulk APIs in China's generics market?
The recent Chinese generics procurement round, where aspirin dropped to 0.034 yuan per tablet, highlights extreme cost pressure across all excipients and APIs. For perspective, domestic aspirin at that price equals roughly 343,000 yuan per tonne, while imported Bayer aspirin after cuts still commands 3.8 million yuan per tonne. This 10-fold gap shows how procurement auctions compress margins for domestic producers. Aspartame, as a high-intensity sweetener, is priced per kilogram, not per tonne, and its cost impact per tablet is minimal—typically fractions of a cent. However, the same logic applies: in bid-based purchasing, every excipient cost is scrutinized. Aspartame's price stability matters less than its functionality. For pharmaceutical-grade aspartame, suppliers like Ajinomoto dominate globally, but Chinese firms—Jiangsu Hanguang, Changzhou Guanghui, Nantong Changhai—are expanding, offering lower prices that could shift procurement decisions in cost-sensitive formulations like pediatric syrups or chewable tablets.